Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 15/20 | 0.76 |
| ▸ | NTRK2 | Q16620 | 15/20 | 0.76 |
| ▸ | IGF1R | P08069 | 5/20 | 0.76 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.76 |
| ▸ | NTRK3 | Q16288 | 11/20 | 0.57 |
| ▸ | BCAT2 | O15382 | 4/20 | 0.41 |
| ▸ | BCAT1 | P54687 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toltrazuril SCHEMBL248912 | 0.88 | NTRK1 (0.57) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| Toltrazuril SCHEMBL21812043 | 0.88 | NTRK1 (0.57) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| Toltrazuril SCHEMBL29509205 | 0.88 | NTRK1 (0.57) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL15783169 | 0.87 | NTRK1 (0.55) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL21295407 | 0.87 | NTRK1 (1.00) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL21305495 | 0.84 | NTRK1 (0.95) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL30743942 | 0.84 | NTRK1 (0.95) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL10975351 | 0.84 | NTRK1 (0.52) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL20306614 | 0.84 | NTRK1 (0.72) | NTRK1NTRK2IGF1RFGFR1NTRK3 | |
| SCHEMBL21295556 | 0.83 | NTRK1 (0.79) | NTRK1NTRK2IGF1RFGFR1NTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200113910-A1 | TRIAZINETRIONE DERIVATIVES AND THEIR USE AS MODULATORS OF NEUROTROPHIN RECEPTOR AND RECEPTOR TYROSINE KINASES | AlzeCure Pharma AB (SE) | 2020-04-16 | — | — | US | disclosed |
| US-20200113910-A1 | TRIAZINETRIONE DERIVATIVES AND THEIR USE AS MODULATORS OF NEUROTROPHIN RECEPTOR AND RECEPTOR TYROSINE KINASES | AlzeCure Pharma AB (SE) | 2020-04-16 | — | — | US | disclosed |
| WO-2018115891-A1 | TRIAZINETRIONE DERIVATIVES AND THEIR USE AS MODULATORS OF NEUROTROPHIN RECEPTOR AND RECEPTOR TYROSINE KINASES | STIFTELSEN ALZECURE (SE) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200113910-A1 | TRIAZINETRIONE DERIVATIVES AND THEIR USE AS MODULATORS OF NEUROTROPHIN RECEPTOR AND RECEPTOR TYROSINE KINASES | NTRK2, NTRK3, BDNF | NTRK1 4/4885NTRK2 1/4885IGF1R 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.